En respuesta a la pandemia actual del COVID-19 (coronavirus), el equipo del estudio ANCHOR ha aconsejado al personal clínico local a que se comunique con los participantes del estudio que ya tienen cita programada durante las próximas 4 semanas para determinar si uno debe acudir a la clínica, o no. Si no recibes noticia del personal clínico de tu local, favor de contactarlos. Si estás en espera de la visita de evaluación, te agradecemos tu paciencia. Sí te atenderemos tan pronto como sea posible, una vez que sea seguro hacerlo. Mientras tanto, puedes comunicarte con tu clínica local del estudio ANCHOR si tienes alguna duda o inquietud.
Ronald Mitsuyasu, M.D.
Dr. Mitsuyasu is the Group Chairman and PI for the AIDS Malignancy Consortium (AMC) and the PI for the UCLA AMC site. He is an ex officio and active member of all of the AMC WG and Committees. He is Professor of Medicine, Division of Hematology-Oncology at UCLA, Director of the UCLA Center for Clinical AIDS Research and Education (CARE Center) and the Associate Director for Clinical Therapeutics and Biomedical Prevention of the UCLA CFAR and AIDS Institute. He has served in leadership positions within both the ACTG and AMC having served as the PI of the UCLA ACTG from 1989 to 2004 and as former chairman of the ACTG Immunology Research Agenda Committee. He is a member of the NCI Board of Scientific Advisors Subcommittee on AIDS Malignancies, the Office of AIDS Research Advisory Council, and he has served on an FDA Advisory Committee, various scientific review boards and study sections and has been the PI of many clinical trials protocols over the past 30 years. He has been a clinical investigator in HIV-associated malignancies since 1982, when he founded the KS clinic at UCLA, and he has conducted trials with immune-based and gene therapy for HIV. The CARE Center’s primary function is to support and conduct clinical investigations in HIV Dr. Mitsuyasu's research interests include clinical investigations of immune-based, biological and genetic therapies for HIV and treatments of HIV-associated malignancies. At UCLA, he will be the administrative director and clinical investigator for the ANCHOR study.